- Home
- EML vs GLSI Comparison
EML vs GLSI Comparison
Compare EML & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- GLSI
- Stock Information
- Founded
- EML 1858
- GLSI 2006
- Country
- EML United States
- GLSI United States
- Employees
- EML N/A
- GLSI N/A
- Industry
- EML Industrial Machinery/Components
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- EML Consumer Discretionary
- GLSI Health Care
- Exchange
- EML Nasdaq
- GLSI Nasdaq
- Market Cap
- EML 130.9M
- GLSI 133.4M
- IPO Year
- EML N/A
- GLSI 2020
- Fundamental
- Price
- EML $22.01
- GLSI $9.64
- Analyst Decision
- EML
- GLSI Strong Buy
- Analyst Count
- EML 0
- GLSI 1
- Target Price
- EML N/A
- GLSI $39.00
- AVG Volume (30 Days)
- EML 9.3K
- GLSI 37.1K
- Earning Date
- EML 05-06-2025
- GLSI 05-20-2025
- Dividend Yield
- EML 1.97%
- GLSI N/A
- EPS Growth
- EML N/A
- GLSI N/A
- EPS
- EML N/A
- GLSI N/A
- Revenue
- EML $271,440,503.00
- GLSI N/A
- Revenue This Year
- EML $6.05
- GLSI N/A
- Revenue Next Year
- EML $7.00
- GLSI N/A
- P/E Ratio
- EML $10.66
- GLSI N/A
- Revenue Growth
- EML 8.15
- GLSI N/A
- 52 Week Low
- EML $19.06
- GLSI $8.06
- 52 Week High
- EML $35.03
- GLSI $18.75
- Technical
- Relative Strength Index (RSI)
- EML 44.17
- GLSI 46.54
- Support Level
- EML $22.60
- GLSI $9.59
- Resistance Level
- EML $23.11
- GLSI $10.10
- Average True Range (ATR)
- EML 0.71
- GLSI 0.54
- MACD
- EML -0.09
- GLSI 0.01
- Stochastic Oscillator
- EML 4.68
- GLSI 27.61
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.